Hepatitis C News

Baseline resistance associated substitutions did not impact sustained virologic response among direct-acting antiviral-experienced patients who underwent hepatitis C therapy with Vosevi for 12 weeks, according to a recently published study.

The World Health Organization has added ravidasvir as a future pangenotypic direct-acting antiviral to the list of recommended therapies in their Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C, according to a press release.

The FDA recently approved safety and efficacy revisions to the Mavyret label based on data from a hepatitis C/HIV-1 collection study and a liver and renal transplant study.

Patients who were negative for hepatitis C virus and received HCV-infected kidneys and antiviral treatment were clear of the disease and experienced good renal function up to a year after transplantation, according to study results recently published in the Annals of Internal Medicine.

Patients without hepatitis C who underwent heart transplantation with an HCV-positive organ were likely to develop HCV viremia posttransplant, but had high rates of sustained virologic response following direct-acting antiviral therapy, according to published results of a recent prospective study.

The American Legion, in partnership with AbbVie, announced the launch of its “Take on Hep C” nationwide initiative designed to provide free hepatitis C antibody testing to veterans and their communities, according to a press release.

“Test. Treat. Hepatitis.” is this year’s World Hepatitis Day theme. The direct-acting antiviral era has seen a significant increase in the number of patients with hepatitis C clearing their infection. Along with this, public awareness of the disease and its highly effective cure has increased.

Growing evidence supports the overall benefits and cost-effective outcomes of testing for and treating hepatitis C in the prison “microenvironment,” according to a review of recent studies.

SeraCare Life Sciences announced the launch of the company’s proprietary AccuSpan HCV RNA Linearity Panel designed to monitor HCV RNA recovery at defined intervals, according to a press release.

Studies that focus on specific patient characteristics and demographics often reveal key strategies to improve health care at the individual patient level. Liver disease research focused on women and mothers has shown that women face fertility risks with hepatitis C and higher risks for liver injury or failure with chronic liver disease.